Founder and CEO | Armatus Bio, Inc.
Dr. Michael Triplett is co-founder, President, and CEO of Armatus Bio, Inc., a gene therapy
company based in Columbus, Ohio developing next generation precision therapies for
genetically driven neuromuscular diseases, and Neucore Bio, Inc., a gene therapy company
developing next generation nonviral precision therapeutics for genetically driven neurological
diseases. Dr. Triplett is co-founder and board co-Chair of Clarametyx Biosciences, Inc., a
preclinical infectious disease company pursuing paradigm shifting therapeutics and vaccines for
the treatment and prevention of bacterial biofilm mediated diseases, after serving as founding
President and CEO. Dr. Triplett co-founded and served as President and CEO of Myonexus
Therapeutics, a clinical stage gene therapy company developing first-ever treatments for limb-
girdle muscular dystrophies that Sarepta Therapeutics acquired in 2019.
Dr. Triplett began his career at Procter & Gamble as a Product Development Engineer prior to
attending graduate school. After completing his graduate work in lipid nanoparticle engineering,
he joined Battelle where he held roles of progressing responsibility, spanning business
development, innovation, new venture development, and strategy.
Dr. Triplett serves on several boards, including Andelyn Biosciences, the InnovateOhio Advisory
Board for the DeWine-Husted administration, the Ohio Federal Research Network Executive
Review Board, the Ohio Life Sciences Association where he is Chair, and the Ohio Gene and
Cell Therapy Council where he is co-Chair. He also serves as a Venture Advisor to the Ohio
Innovation Fund, a Columbus, Ohio based venture capital fund. Dr. Triplett is a Founding Partner
of Carmen Ventures, an emerging venture capital fund created by Ohio State University alumni
with the mission of investing in Ohio State University alumni led and IP based ventures.